Two Incretin Peptides. One Research Record.

The short version

Assent Peptides is a reading desk, not a store. It collects what the published research literature actually says about two incretin-class peptides that sit at the center of current metabolic and weight-management research: retatrutide and tirzepatide. A peptide is a short chain of amino acids — the building blocks of proteins, only far smaller and far more targeted. Both compounds work by engaging receptors in the gut and brain that regulate appetite, insulin secretion, and energy use. The difference is in scope: tirzepatide targets two receptors (GIP and GLP-1) and is FDA-approved; retatrutide targets three (GIP, GLP-1, and glucagon) and is still in Phase 3 trials ^[1][4][9].

This digest does one job. It tells you, in plain language and with citations, what each compound was tested on, in which people, and how far the evidence reaches. No products are sold here. No dose is recommended. No brand names are used — only the international nonproprietary names.

What are research peptides?

Peptides are chains of amino acids joined together — shorter than proteins but specific enough to act as keys that fit particular locks (receptors) on cell surfaces, switching physiological processes on or off. The incretin peptides on this desk mimic or amplify natural hormones the body already uses to coordinate blood sugar, appetite, and energy expenditure after eating.

A research peptide is one studied in clinical trials or laboratory settings that either has not yet received regulatory approval, or has received approval for specific indications only. When this site reports a finding, it reports it the way the study did — for example, studied at 12 mg once weekly in adults with obesity — never as a recommendation for any individual.

How these two fit into metabolic research

Retatrutide and tirzepatide represent two generations of incretin pharmacology, each extending the approach of the last.

• Retatrutide is the lead. It is an investigational 39-amino-acid peptide that agonizes three receptors simultaneously — GIP, GLP-1 and glucagon. The glucagon arm adds energy expenditure and lipid mobilization beyond what dual agonists achieve, and Phase 2 data show mean body-weight reductions of up to 24.2% at 48 weeks in adults with obesity — a figure that exceeded prior trials of single or dual incretin agents ^[4]. Phase 3 is ongoing; no regulatory approval exists as of mid-2026 ^[1].
• Tirzepatide is the approved dual agonist. It activates both the GIP and GLP-1 receptors with a single 39-amino-acid molecule and received FDA approval for type 2 diabetes in 2022, followed by approvals for obesity and obstructive sleep apnea. In a direct head-to-head Phase 3b trial it produced greater weight loss than the maximum tolerated dose of semaglutide over 72 weeks ^[8][9].

Together they map the trajectory of incretin pharmacology — from dual to triple agonism — and raise sharply different questions about evidence strength, regulatory status, and clinical certainty. Use the pages to read each one in detail, or compare these peptides side by side.

A note on how this desk reads the literature

Assent Peptides is a citation-anchored literature digest. Each compound page summarizes peer-reviewed studies, cites them by number, and links to a single shared references list that aggregates every source. Where data are from a Phase 2 trial rather than an approved indication, we say so. Where a compound is investigational, that is stated plainly. Findings are described at the precision of their study populations — not extrapolated to general recommendations. The desk's aim is a clear, accurate account of what the literature shows, so a reader can see where the evidence is solid and where uncertainty remains.